Enhanced Exposure of the CD4-Binding Site to Neutralizing Antibodies by Structural Design of a Membrane-Anchored Human Immunodeficiency Virus Type 1 gp120 Domain
暂无分享,去创建一个
Tongqing Zhou | Gary J. Nabel | Peter D. Kwong | John R. Mascola | Dennis R. Burton | Ling Xu | Mark K. Louder | R. Doms | J. Hoxie | J. Mascola | D. Burton | G. Nabel | T. Zhou | M. Louder | P. Kwong | S. O'dell | Lan Wu | Ling Xu | Krisha Svehla | Robert W. Doms | Zhi-yong Yang | James A. Hoxie | Sijy O'Dell | Lan Wu | K. Svehla | S. O’dell | Zhi-yong Yang | Krisha Svehla
[1] John R. Mascola,et al. Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals , 2008, Journal of Virology.
[2] Mark Connors,et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies , 2007, Nature Medicine.
[3] A. Trkola,et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.
[4] R. Doms,et al. V3 Loop Truncations in HIV-1 Envelope Impart Resistance to Coreceptor Inhibitors and Enhanced Sensitivity to Neutralizing Antibodies , 2007, PLoS pathogens.
[5] H. Katinger,et al. The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose Residues on the Outer Face of gp120 , 2002, Journal of Virology.
[6] J. Sodroski,et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.
[7] F. Gao,et al. Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope. , 2004, Virology.
[8] J. Sodroski,et al. Effects of changes in gp120-CD4 binding affinity on human immunodeficiency virus type 1 envelope glycoprotein function and soluble CD4 sensitivity , 1991, Journal of virology.
[9] Z. Xiang,et al. Targeted deletion in the beta20-beta21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding. , 2008, Virology.
[10] Peter D. Kwong,et al. The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.
[11] S. Zolla-Pazner,et al. Human monoclonal antibodies to the V3 loop of HIV-1 gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site. , 1993, Journal of acquired immune deficiency syndromes.
[12] J. Mascola,et al. Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope. , 2006, Vaccine.
[13] Paul W. H. I. Parren,et al. Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120 , 2003, Journal of Virology.
[14] Punnee Pitisuttithum,et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. , 2006, The Journal of infectious diseases.
[15] Xiping Wei,et al. Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.
[16] Wayne C Koff,et al. HIV vaccine design and the neutralizing antibody problem , 2004, Nature Immunology.
[17] C. Barbas,et al. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[18] Dennis R. Burton,et al. Identification and Characterization of a New Cross-Reactive Human Immunodeficiency Virus Type 1-Neutralizing Human Monoclonal Antibody , 2022 .
[19] J. Sodroski,et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding , 1993, Journal of virology.
[20] K. Sharp,et al. Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons , 1991, Proteins.
[21] Tongqing Zhou,et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.
[22] D. Ho,et al. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody , 1991, Journal of virology.
[23] D R Burton,et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.
[24] L. Cavacini,et al. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. , 1993, Journal of acquired immune deficiency syndromes.
[25] Jonathan M Gershoni,et al. Computational prediction of the cross‐reactive neutralizing epitope corresponding to the monoclonal antibody b12 specific for HIV‐1 gp120 , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[26] Daniel C. Douek,et al. The Rational Design of an AIDS Vaccine , 2006, Cell.
[27] S. Rybak,et al. Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. , 2003, Journal of immunological methods.
[28] S. Hammer,et al. HIV Vaccine Research: The Way Forward , 2008, Science.
[29] Kenneth H Mayer,et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. , 2005, The Journal of infectious diseases.
[30] D R Burton,et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.
[31] W. Blattner,et al. Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120: Negative Results Fail to Trigger a Phase 3 Correlates Trial , 2007, Journal of acquired immune deficiency syndromes.
[32] J. Hoxie,et al. Effects of Partial Deletions within the Human Immunodeficiency Virus Type 1 V3 Loop on Coreceptor Tropism and Sensitivity to Entry Inhibitors , 2007, Journal of Virology.
[33] Dennis R. Burton,et al. Toward an AIDS Vaccine , 2008, Science.
[34] D. Montefiori,et al. Modifications of the Human Immunodeficiency Virus Envelope Glycoprotein Enhance Immunogenicity for Genetic Immunization , 2002, Journal of Virology.
[35] D E McRee,et al. XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density. , 1999, Journal of structural biology.
[36] J. Sodroski,et al. Characterization of the Outer Domain of the gp120 Glycoprotein from Human Immunodeficiency Virus Type 1 , 2004, Journal of Virology.
[37] J. Sodroski,et al. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein , 1996, Journal of virology.
[38] Bette Korber,et al. Structure of a V3-Containing HIV-1 gp120 Core , 2005, Science.
[39] Don C. Wiley,et al. Structure of an unliganded simian immunodeficiency virus gp120 core , 2005, Nature.